Abbott has been granted an Emergency Use Authorization (EUA) by the FDA for use of its coronavirus molecular test on its Alinity m molecular diagnostics analyzer.

The company is currently launching the Alinity m analyzer, which received FDA marketing clearance in March for use with its hepatitis C assay.

The automated platform can run up to 1,080 tests in 24 hours. In contrast, Abbott’s m 2000 RealTime system can only process 480 tests in a day.